TEVA Bathi saben saham sajrone rolas wulan pungkasan Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries (TEVA) generates revenue through the global sale of generics and the drug Austedo, leveraging economies of scale and B2B relationships with pharmacies. The TTM earnings per share metric helps filter out market noise, while the value of 0.42 serves as the target level. Profit growth is constrained by prolonged regulatory approvals and complex patent disputes with original brand owners.
Rincian metrik keuangan lan pasar Teva Pharmaceutical Industries Ltd. (TEVA)

Teva Pharmaceutical Industries (TEVA) leverages its generic production scale to create pricing power, yet regulatory pressure in the US and EU directly impacts the TTM net income per share trend. This metric aggregates trailing twelve-month profit per share, neutralizing accounting noise and allowing investors to assess real capital generation efficiency regardless of the securities' issuance structure.